Analgesic Effects of Toad Cake and Toad-cake-containing Herbal Drugs

다국어 초록 (Multilingual Abstract)

Objectives: This study was conducted to clarify the analgesic effect of toad cake and toad-cake-containing herbal drugs.
Methods: We counted the writhing response of mice after the intraperitoneal administration of acetic acid as a nociceptive pain model and the withdrawal response after the plantar surface stimulation of the hind paw induced by partial sciatic nerve ligation of the mice as a neuropathic pain model to investigate the analgesic effect of toad cake and toad-cake-containing herbal drugs. A co-treatment study with serotonin biosynthesis inhibitory drug 4-chloro-DL-phenylalanine methyl ester hydrochloride (PCPA), the catecholamine biosynthesis inhibitory drug α-methyl-DL-tyrosine methyl ester hydrochloride (AMPT) or the opioid receptor antagonist naloxone hydrochloride was also conducted.
Results: Analgesic effects in a mouse model of nociceptive pain and neuropathic pain were shown by oral administration of toad cake and toad-cake-containing herbal drugs. The effects of toad cake and toad-cake-containing herbal drugs disappeared upon co-treatment with PCPA, but not with AMPT or naloxone in the nociceptive pain model; the analgesic effect of toad-cake-containing herbal drugs also disappeared upon co-treatment with PCPA in the neuropathic pain model.
Conclusion: Toad cake and toad-cake-containing herbal drugs have potential for the treatments of nociceptive pain and of neuropathic pain, such as post-herpetic neuralgia, trigeminal neuralgia, diabetic neuralgia, and postoperative or posttraumatic pain, by activation of the central serotonin nervous system.

참고문헌 (Reference)

1 Namba T., "The Encyclopedia of Wakan-Yaku: traditional Sino-Japanese medicines (2)" Hoikusha 270-, 1985

2 Therapy guideline committee of Japanese Society of Neurological Therapentics, "Standard medical therapy of nerve pain, chronic pain]" 27 : 591-622, 2007

3 Chodera A., "Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals" 16 (16): 357-360, 1978

4 Nakagawa T., "SNRI. NaSSA" 64 (64): 105-111, 2013

5 Morishita S., "Pharmacological studies of"reiousan"which contains bezoar and ginseng" 91 (91): 129-140, 1988

6 Morishita S., "Pharmacological studies of Senso(Ch’an Su)containing drugs" 87 (87): 361-378, 1986

7 Dworkin RH., "Pharmacologic management of neuropathic pain : evidence-based recommendations" 132 (132): 237-251, 2007

8 Ookoshi N., "Pain" 63 (63): S125-S127, 2012

9 "No. P2012-51217. Japanese Patent Application"

10 Mazzardo-Martins L., "Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice : evidence for the mechanisms of action" 226 : 411-420, 2012

11 Honda K., "Experimental methods in pain using neuropathic and inflammatory animal models" 130 (130): 39-44, 2007

12 Vanegas H., "Descending control of persistent pain : inhibitory or facilitatory?" 46 (46): 295-309, 2004

13 "Chuyaku Dijiten, vol 2" Shanghai Scientific and Technical Publishers 1521-1524, 1985

14 Yanase T., "Antinociceptive effects of Kami-kihi-to in mice" 108 (108): 77-83, 1996

15 The 54th annual meeting organising committee of the Japanese Society of Pharmacognosy, "Abstracts on the 54th annual meeting of the Japanese Society of Pharmacognosy" 2007

16 The 131th annual meeting organising committee of the Pharmaceutical Society of Japan, "Abstracts for 2nd on the 131th annual meeting of the Pharmaceutical Society of Japan" 2011

17 Seltzer Z., "A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury" 43 (43): 205-218, 1990